Posts filtered by tags: Biogen[x]


 

Alzheimer's nasal vaccine to enter human trials for the first time, spurring renewed hope for preventing the disease

A laboratory worker tests a nasal spray (not related to Alzheimer's) at the Pharma and Beauty factory in Saint-Chamas, France, on January 21, 2021.Nicolas Tucat/AFP/Getty Images Brigham and Women's Hospital is spearheading the first human trial of an Alzheimer's nasal vaccine. The vaccine is designed to prevent or slow the progression of the disease. It uses a drug, Protollin, to stimulate immune cells to remove sticky plaque from the brain. Alzheimer's treatments seemed like ...
Tags: Science, News, Drugs, US, Trends, Alzheimer's Disease, Food And Drug Administration, Fda, Vaccines, Eisai, Cummings, Brigham, Alzheimer, University of Nevada Las Vegas, William Burke, Biogen


CDC backs boosters for all vaccinated adults

Hello,Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, here to kick off this holiday week. Today in healthcare news:The CDC has endorsed booster shots for adults after the FDA gave the OK;Dr. Fauci tells Insider he doesn't see a reason to wait to vaccinate kids 5-11 against COVID-19;A major study evaluates the use of masks in preventing COVID-19.If you're new to this newsletter, sign up here. Comments, tips? Find me at [email protected] or @lydiaramsey125. Let's get to...
Tags: Europe, Cdc, Washington, Masks, US, Trends, Bloomberg, Austria, Healthcare, Fda, Pfizer, Vaccines, Anthony Fauci, Elizabeth Holmes, Fauci, Biogen


Biogen's Alzheimer's Drug Gets Negative Vote From EMA Panel

(Reuters) -Biogen Inc said on Wednesday a European Medicines Agency panel has voted against the marketing application for its Alzheimer's disease...
Tags: European Medicines Agency, Biogen, Reuters Biogen Inc, EMA Panel


Biogen's Alzheimer's Drug Gets Negative Vote From European Panel

(Reuters) -Biogen Inc's marketing application for its Alzheimer's disease drug was voted down by a European Medicines Agency (EMA) panel, in the...
Tags: Biogen, European Medicines Agency EMA, Reuters Biogen Inc


Biogen's Research Chief Alfred Sandrock to Retire

(Reuters) - Biogen Inc said on Monday its research chief Alfred Sandrock, who led development of its Alzheimer's disease drug Aduhelm, is leaving...
Tags: Biogen, Reuters Biogen Inc, Alfred Sandrock


Biogen CEO: 'Major Bottleneck' Still Limits Alzheimer's Drug

A new Alzheimer’s drug from Biogen brought in only $300,000 in sales during its first full quarter on the market, continuing a slow debut complicated by coverage questions and doctor concerns.
Tags: Biogen


Biogen Posts Much Smaller-Than-Expected Sales of New Alzheimer's Drug

(Reuters) - Biogen Inc fell well short of Wall Street estimates for third-quarter sales of its Alzheimer's drug Aduhelm on Wednesday, as the...
Tags: Biogen, Reuters Biogen Inc


Biogen Raises Forecast Despite Disappointing Alzheimer's Drug Sales

(Reuters) -Biogen Inc raised its full-year profit and revenue forecasts on Wednesday, while reporting a big miss on quarterly sales of its...
Tags: Biogen, Reuters Biogen Inc


Biogen Sales Face Pressure From Slow Uptake of Alzhiemer's Drug

By Dania Nadeem and Amruta Khandekar(Reuters) - Biogen Inc's Alzheimer's drug will be of little help to its third-quarter sales, Wall Street...
Tags: Biogen, Dania Nadeem, Amruta Khandekar Reuters Biogen Inc


Biogen Trial of ALS Drug Fails Main Goal, but Company Says Data Are Encouraging

By Deena Beasley(Reuters) - A late-stage trial of Biogen Inc's experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS)...
Tags: Biogen Inc, Biogen, Deena Beasley Reuters


Apple Working on Depression Detection for iPhones: Report

Apple is reportedly partnering with UCLA and Biogen to see if health data can be used to detect depression, anxiety, and cognitive decline.
Tags: Apple, Ucla, Biogen


Apple is researching whether its iPhone could help detect depression, a report says

Apple CEO Tim Cook. Apple Apple is researching whether data from its iPhone could help detect depression, the WSJ reported. Scientists are studying sleep and typing data to try to detect patterns linked to health conditions, per the report. The project is early stage and may not lead to new features, sources said. See more stories on Insider's business page. Apple wants to know whether its devices could help detect depression early, according to a report from The Wall Street Journal.It...
Tags: Iphone, Apple, Science, News, US, Trends, Healthcare, Dementia, Duke, Journal, WSJ, Ucla, Duke University, Biogen, University of California Los Angeles UCLA, Seabreeze


Apple Researching Ways to Use iPhone Camera to Detect Childhood Autism

Apple is reportedly researching ways to use the cameras inside of the iPhone to detect childhood autism, aiming to use data from the camera to observe a child's behavior that could be used for early diagnosis, according to a new report from The Wall Street Journal. According to the report, which echoes previously announced research efforts, Apple wants to be able to use the camera inside of the ‌iPhone‌ to track a child's face and observe different facial behaviors, such as how often they loo...
Tags: Apple, The Wall Street Journal, Wall Street Journal, Journal, Duke University, Biogen


Patent Law at the Supreme Court September 2021

by Dennis Crouch So far, the Supreme Court has not granted certiorari in any patent cases for its 2021-2022 Term.  Still, there are a couple dozen cases pending that may offers some interest.  On September 27, 2021, the court is meeting privately for what is known as the “long conference” to decide the fate of the petitions for writ of certiorari that have piled-up over the summer.  There are also a host of additional petitions scheduled for a later conference or not yet scheduled.  Although th...
Tags: Supreme Court, Law, Court, New Jersey, Uspto, Patent, Apple Inc, Kessler, Fed, The Supreme Court, Biogen, Federal Circuit, Samsung Electronics America Inc, Cisco Systems Inc, Hu, IPR


U.S. Congress Seeks Information From FDA on Approval of Biogen's Alzheimer's Drug

(Reuters) - U.S. lawmakers have requested data and documents from the Food and Drug Administration (FDA) related to its accelerated approval of...
Tags: Reuters U S, Food and Drug Administration FDA, Biogen, Congress Seeks Information From FDA


Congress Requests Documents From FDA on Approval of Biogen's Alzheimer's Drug - Stat News

(Reuters) - Two House Committees have requested data and documents from the Food and Drug Administration related to the agency's accelerated...
Tags: Food And Drug Administration, Reuters, Biogen, Congress Requests Documents From FDA


Biogen Provides Free Aduhelm as U.S. Clinics Await Medicare Payment

By Deena Beasley(Reuters) - Biogen Inc is providing its controversial and expensive new Alzheimer's drug free of charge for some patients amid slow...
Tags: Biogen, Deena Beasley, Reuters Biogen Inc


Warren Buffett's Berkshire Hathaway sold Biogen, halved its Merck stake, and boosted its Kroger bet. Here's a closer look at its key trades in Q2.

Warren Buffett. Getty Images / Matthew Peyton Warren Buffett's Berkshire Hathaway sold its Biogen stock and slashed its Merck stake last quarter. The investor's company bought more Kroger shares, and has now tripled its stake in 18 months. Here's a closer look at some of its key trades in the second quarter. See more stories on Insider's business page. Warren Buffett's Berkshire Hathaway sold all of its Biogen stock, slashed its Merck stake, and ramped up its Kroger pos...
Tags: Trends, Merck, Berkshire Hathaway, Warren Buffett, Pfizer, Abbvie, Berkshire, Wells Fargo, Buffett, Kroger, Jpmorgan, Bristol Myers Squibb, Biogen, Theron Mohamed, Warren Buffett Getty, Matthew Peyton Warren Buffett


Warren Buffett's Berkshire Hathaway sold its Biogen stake last quarter - and slashed its pharmaceutical bets

Warren Buffett. REUTERS/Mario Anzuoni Warren Buffett's Berkshire Hathaway exited its Biogen and Axalta bets last quarter. Buffett's company trimmed its pharmaceutical positions and sold some Chevron and GM stock. The investor and his team increased their stakes in Aon, Kroger, and RH. See more stories on Insider's business page. Warren Buffett's Berkshire Hathaway sold its stakes in Biogen and Axalta, trimmed its pharmaceutical bets, and added to a handful of positions in t...
Tags: Trends, General Motors, Merck, Gm, Berkshire Hathaway, Warren Buffett, Chevron, Berkshire, Wells Fargo, Buffett, Kroger, Biogen, Aon, Axalta, Organon, SPACs


The CDC is urging coronavirus vaccines for pregnant people

Hello,Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and today in healthcare news:The CDC wants pregnant people to get the coronavirus vaccine urgently;More from our interview with CDC Director Rochelle Walensky, including a message for people who think the pandemic isn't a big deal;Doctors share what it's like inside Austin hospitals right now as they reach capacity.If you're new to this newsletter, sign up here. Comments, tips? Email me at [email protected] or twee...
Tags: Florida, Texas, Cdc, US, Trends, Austin, Healthcare, Associated Press, Vaccines, Cuomo, Houston Texas, Pontiac Michigan, Biogen, Newsletters, Aubrey de Grey, United Memorial Medical Center


Aduhelm approval sparks HHS watchdog review of FDA’s accelerated approval pathway

The Department of Health and Human Services (HHS) Office of the Inspector General will review the FDA’s accelerated approval pathway, the office announced Wednesday. This sweeping review comes just two months after the controversial approval of Biogen’s Alzheimer’s drug Aduhelm. The review will focus on the FDA’s accelerated approval pathway – a route that allows drugs for serious diseases without existing treatments to be approved if they hit certain interim benchmarks (called surrogate ...
Tags: Tech, Fda, Cleveland Clinic, HHS, Biogen, Eli Lilly, Woodcock, HHS OIG, Janet Woodcock, Aduhelm, Project Onyx, Daniel M Skovronsky, Controversial FDA


The 9 behind-the-scenes professionals you need to know in digital health

Hello,Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and today in healthcare news:We found 9 players working behind the scenes who can make or break a digital health startup;It's back to wearing masks indoors, even for those fully vaccinated, CDC says;Here's the presentation Deep Genomics used to raise $180 million from investors including SoftBank and Khosla.If you're new to this newsletter, sign up here. Comments, tips? Email me at [email protected] or tweet @lydia...
Tags: Cdc, Softbank, Masks, US, Toronto, Trends, Cnn, Healthcare, Delta, Wu Tang, Andreessen Horowitz, Biden, Khosla, Orlando Florida, Biogen, Newsletters


Maker of Dubious $56K Alzheimer's Drug Offers Cognitive Test No One Can Pass

An anonymous reader quotes a report from Ars Technica: Do you ever forget things, like a doctor's appointment or a lunch date? Do you sometimes struggle to think of the right word for something common? Do you ever feel more anxious or irritable than you typically do? Do you ever feel overwhelmed when trying to make a decision? If you answered "no, never" to all of those questions, there's a possibility that you may not actually be human. Nevertheless, you should still talk to a doctor about addi...
Tags: Tech, Fda, Georgetown University, Biogen


HealthDay Now: Experts Weigh In On Alzheimer's Drug Controversy

In a HealthDay Now interview, Mabel Jong heard from experts with inside knowledge on the FDA's controversial approval of aducanumab. First up is Dr. G. Caleb Alexander, a professor at Johns Hopkins who served on the FDA advisory committee that nearly unanimously advised against approving Biogen's controversial new Alzheimer's drug. Then, a conversation between Dr. Anton Porsteinsson, a principal investigator for the drug trial, and Dr. Ken Lin, a primary care physician who, like most clinicians ...
Tags: Fda, Johns Hopkins, Biogen, Ken Lin, Mabel Jong, G Caleb Alexander, Anton Porsteinsson


Facing headwinds on new Alzheimer’s drug, Biogen launches controversial campaign

Do you sometimes lose your train of thought or feel a bit more anxious than is typical for you?
Tags: Health, Biogen


Biogen Raises 2021 Revenue Forecast, Defends Alzheimer's Drug Approval

(Reuters) -Biogen Inc on Thursday raised its full-year revenue expectations, and defended the approval of its Alzheimer's disease drug by the U.S....
Tags: Biogen, Reuters Biogen Inc


Biogen Defends Alzheimer's Drug Approval, Reports $2 Million in Early Sales

(Reuters) -Biogen Inc on Thursday said the approval of its Alzheimer's disease drug was based on extensive data as it seeks to quell concerns about...
Tags: Biogen, Reuters Biogen Inc


Biogen Pushes Back Against Critics of Alzheimer's Drug as Early Sales Hit $2 Million

(Reuters) -Biogen Inc on Thursday mounted a defense of its interactions with U.S. regulators that led to a controversial approval of its new...
Tags: Biogen, Reuters Biogen Inc


Analysis - Biogen Alzheimer's Drug Slow to Take off as U.S. Medicare Wrestles With Coverage

By Deena Beasley(Reuters) - U.S. hospitals that were expected to be early adopters of Biogen’s Alzheimer’s drug have treated only a handful of...
Tags: Biogen, Deena Beasley Reuters U


New Treatments for Alzheimer’s Disease

A new Biogen drug offers promise and controversy in the quest for an Alzheimer’s cure.
Tags: Biogen